17. November 2009 03:36
Genentech, Inc., a wholly-owned member of the Roche Group, today announced that the company submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the Phase III study AVADO that investigated Avastin in combination with docetaxel chemotherapy.
[More]
52d6ae04-8005-4377-aa8f-72b645331f28|0|.0
Posted in: Women's Health News | Pharmaceutical News
Tags: Abdominal Pain, Angiogenesis, Anthracycline, Antibody, Avastin, Back Pain, Bevacizumab, Biotechnology, Birth Control, Blood Pressure, Blood Vessel, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Chemotherapy, Congestive Heart Failure, Dehydration, Dermatitis, Diarrhea, Docetaxel, Fertility, Fistula, Headache, Heart Failure, Low Blood Pressure, Nausea, Nervous System, Paclitaxel, Pregnancy, Stroke, VEGF, Vomiting, Wound Healing
11. November 2009 03:43
An analysis conducted by the Finnish Breast Cancer Group and published in The Lancet Oncology shows women at intermediate to high-risk of early breast cancer recurrence who received capecitabine as part of their chemotherapy regimen had a 34% reduction in the risk of the disease returning or death, compared with those taking the chemotherapy combination regimen without capecitabine.
[More]
f9a26b2b-e4b5-4bd0-9640-1af3a9b6dbc7|0|.0
Posted in: Women's Health News | Pharmaceutical News
Tags: Adjuvant Therapy, Breast Cancer, Cancer, Capecitabine, Chemotherapy, Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Hospital, Metastasis, Oncology, Xeloda
6. November 2009 07:38
ZIOPHARM Oncology, Inc. presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma.
[More]
c33ab7fd-4a47-496c-ab34-49adcecd0d14|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Alopecia, Anemia, Arsenic, Bone, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Cyclophosphamide, Doxorubicin, Gleevec, Lymphoma, Nausea, Neuropathy, Neutropenia, New Drug Application, Oncology, Soft Tissue Sarcoma, Testicular Cancer, Xeloda
22. October 2009 08:08
Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.
[More]
fc89edfd-87d8-443c-bf50-560729ad8450|0|.0
Posted in: Business / Finance
Tags: Abilify, Angioplasty, Antibody, Apixaban, Arthritis, Cancer, Capecitabine, Cardiology, Chemotherapy, Colorectal Cancer, Diabetes, Diabetes Mellitus, Hemostasis, Hepatitis B, Immunology, Medicaid, Medicare, Metformin, Nutrition, Oncology, Onglyza, Oxaliplatin, Plavix, Prescription Drug, Rheumatoid Arthritis, Saxagliptin, Sprycel, Stroke, Thrombosis, Type 2 Diabetes
14. October 2009 09:16
ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed.
[More]
f334ff73-856d-4d23-b058-7564a6af3f67|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Alopecia, Anemia, Arsenic, Brain, Breast Cancer, Cancer, Capecitabine, Cell, Cyclophosphamide, Doxorubicin, Lymphoma, Nausea, Neuropathy, Neutropenia, New Drug Application, Oncology, Soft Tissue Sarcoma, Xeloda
23. September 2009 08:48
The retrospective CRYSTAL analysis was conducted as a result of an effort to increase the tissue ascertainment rate to determine the K-ras status of patients’ tumors. The analysis included extended patient follow up of nearly 1.5 years and doubled the tissue ascertainment rate from 45% to 89%. These data are an update from the overall survival results from CRYSTAL that were published in the April 2009 issue of the New England Journal of Medicine.
[More]
549f4d18-41fe-41e2-8626-3c82cb4e91ef|1|5.0
Posted in: Drug Trial News | Medical Condition News
Tags: Cancer, Capecitabine, Cellulitis, Cetuximab, Chemotherapy, Colorectal Cancer, Conjunctivitis, Diarrhea, Headache, Irinotecan, Oxaliplatin, Pregnancy, Renal Failure, Sepsis
23. September 2009 07:13
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.
[More]
5cc2d3f1-c2a5-43b2-bf2b-10ddd6949979|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Abdominal Pain, Adjuvant Therapy, Alopecia, Angiogenesis, Bevacizumab, Blood Pressure, Breast Cancer, Cancer, Capecitabine, Cardiology, Cell, Cell Proliferation, Chemotherapy, Colorectal Cancer, Diabetes, Diarrhea, Docetaxel, Dyspnea, Gemcitabine, Hematology, Hepatocellular Carcinoma, Kidney Cancer, Liver Cancer, Multiple Sclerosis, Nausea, Neutropenia, Nexavar, Oncology, Paclitaxel, Sorafenib, Weight Loss
23. September 2009 07:09
One of the first of a series of trials to investigate the use of sorafenib - a targeted anti-cancer drug - for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.
[More]
17. September 2009 04:33
Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.
[More]
54c3c369-cebf-4d35-a645-7c58d7108427|0|.0
Posted in: Drug Trial News
Tags: Abdominal Pain, Adjuvant Therapy, Alopecia, Angiogenesis, Apoptosis, Blood Pressure, Bone, Breast Cancer, Cancer, Capecitabine, Cardiology, Cell, Cell Proliferation, Colorectal Cancer, Diabetes, Diarrhea, Hematology, Hepatocellular Carcinoma, Kidney Cancer, Kinase Inhibitor, Liver Cancer, Lung Cancer, Nausea, Nexavar, Oncology, Ovarian Cancer, Prostate Cancer, Renal Cell Carcinoma, Sorafenib, Thyroid Cancer, Weight Loss
11. September 2009 07:15
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, continues to drive the global effort to ensure patients receive personalized cancer therapies. A total of 17 abstracts concerning Merck Serono oncology treatments will be presented at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), to be held in Berlin from 20-24 September 2009.
[More]
050366a4-e745-4952-a42f-464a79c8e48f|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Acne, Antibody, Cancer, Capecitabine, Cell, Cetuximab, Chemotherapy, Colorectal Cancer, Endocrinology, Fertility, Glioblastoma, Hypersensitivity, Infertility, Irinotecan, Liposome, Lung Cancer, Metformin, Monoclonal Antibody, Multiple Sclerosis, Non-Small Cell Lung Cancer, Oncology, Oxaliplatin, Radiotherapy, Small Cell Lung Cancer, Squamous Cell Carcinoma, Vaccine
9. September 2009 00:48
Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumor response and longer survival.
[More]
ffc1b897-e3c7-4846-8fb5-61dcccab6bf3|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Breast Cancer, Cancer, Capecitabine, Chemotherapy, Diarrhea, Gastroenterology, Hepatocellular Carcinoma, Liver Cancer, Nausea, Oncology, Pharmacology, Sorafenib
18. August 2009 02:13
Genentech, Inc. today announced that a Phase III study (RIBBON 2) of Avastin (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.
[More]
b1f87360-780a-44da-b3d5-4ffde727ec43|0|.0
Posted in: Drug Trial News
Tags: Angiogenesis, Anthracycline, Antibody, Avastin, Back Pain, Bevacizumab, Biotechnology, Blood Pressure, Blood Vessel, Brain, Breast Cancer, Cancer, Capecitabine, Carboplatin, Cell, Chemotherapy, Colorectal Cancer, Corticosteroid, Dermatitis, Diarrhea, Docetaxel, Edema, Fertility, Fistula, Gemcitabine, Glioblastoma, Lung Cancer, Neuropathy, Non-Small Cell Lung Cancer, Paclitaxel, Pregnancy, Radiation Therapy, Renal Cell Carcinoma, Rhinitis, Small Cell Lung Cancer, Stroke, VEGF, Vinorelbine
10. August 2009 18:13
Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.
[More]
04a3d54a-c6c5-434a-8a3e-2410ec0c6429|0|.0
Posted in: Business / Finance
Tags: Ankylosing Spondylitis, Biotechnology, Bone, Breast Cancer, Cancer, Capecitabine, Cell, Diabetes, Docetaxel, Gemcitabine, Gemzar, Inflammatory Disease, Leukemia, Melanoma, Methotrexate, Multiple Myeloma, Taxotere, Type 2 Diabetes, Xeloda
26. May 2009 19:09
Immigration officials held a cancer patient for four hours before they allowed him to enter the USA because one of his cancer drugs caused his fingerprints to disappear. His oncologist is now advising all cancer patients who are being treated with the commonly used drug, capecitabine, to carry a doctor's letter with them if they want to travel to the USA.
[More]
17. May 2009 05:25
At the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), researchers from the Mayo Clinic campus in Florida report that using a combination of capecitabine, vinorelbine, and trastuzumab offers a treatment option that is at least as beneficial as other current options - and doesn't cause hair loss in patients.
[More] 
Subscribe